| Bioactivity | Palbociclib-d8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1]. | ||||||||||||
| Name | Palbociclib-d8 | ||||||||||||
| CAS | 1628752-83-9 | ||||||||||||
| Formula | C24H21D8N7O2 | ||||||||||||
| Molar Mass | 455.58 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. |
Palbociclib-d8
CAS: 1628752-83-9 F: C24H21D8N7O2 W: 455.58
Palbociclib-d8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.